However, in TRAIL‐resistant CRC cells, the effectiveness of recombinant TRAIL protein in killing cancer cells is limited, and clinical trials using recombinant TRAIL or TRAIL‐based combinations with antitumor drugs have not yielded the expected outcomes.48, 49, 50, 51. This evidence concerns the gene TNFSF10 and colorectal carcinoma.